Patel Chem Specialities Limited will hold its 18th Annual General Meeting on September 25, 2026, at its registered office in Ahmedabad. The meeting agenda includes the adoption of audited financial statements for FY26 and the ratification of cost auditor remuneration.

Key Resolutions

The Board has placed two special business items before shareholders for approval via ordinary resolutions.

Cost Auditor Remuneration

Shareholders are asked to ratify the remuneration payable to M/s. B R S & Associates for conducting the cost records audit for FY27. The approved fee is ₹1,00,000 plus applicable taxes and reimbursement of out-of-pocket expenses. This appointment was initially approved by the Board on May 22, 2026.

Related Party Transactions

The Company seeks omnibus approval for related-party transactions with an aggregate value not exceeding ₹65 crore (excluding taxes). These transactions are proposed to be entered into on an arm’s length basis in the ordinary course of business. The approval remains valid until the next AGM.

The proposed transactions involve sales, purchases, rent, managerial remuneration, and loan acceptances from entities controlled by or associated with the Managing Director and Whole-Time Director.

Director Re-appointment

Mrs. Anshu Bhupesh Patel retires by rotation and offers herself for re-appointment as a Director. She has served on the Board since October 1, 2011, and was appointed as Whole-Time Director effective September 20, 2024. Her remuneration for FY26 was ₹40,32,000. She holds 14,96,000 equity shares in the Company.

Voting Process

Remote e-voting opens on September 22, 2026, at 10:00 am and closes on September 24, 2026, at 5:00 pm. The cut-off date for eligibility is September 18, 2026. Shareholders holding securities in demat mode can vote through NSDL or CDSL portals, while those with physical shares or non-individual demat holdings must use the InstaVote facility provided by MUFG Intime India Private Limited.

Patel Chem Specialities reported a 30.6% year-on-year rise in revenue to ₹1,372.6 crore for the financial year ended March 31, 2026. Net profit increased by 18.7% to ₹125.5 crore, supported by strong domestic demand and the successful completion of its initial public offering.

The Ahmedabad-based manufacturer of pharmaceutical excipients saw its EBITDA grow by 20.1% to ₹188.9 crore. While revenue growth outpaced profit growth, the company maintained healthy operating earnings despite higher capital expenditure on new manufacturing facilities.

Financial Performance

Revenue from operations stood at ₹1,372.6 crore in FY26, compared to ₹1,050.9 crore in the previous year. The top-line expansion was driven by higher business volumes and stronger demand across its product portfolio, including sodium CMC and croscarmellose sodium.

Profit after tax rose from ₹105.7 crore to ₹125.5 crore. The pace of net profit growth remained moderated relative to revenue growth, reflecting the impact of increased operational scale and investments in infrastructure.

What the Numbers Show

EBITDA margin contracted to 13.6% in FY26 from 15.0% in FY25. This divergence between robust revenue growth and margin compression suggests that cost of materials or operating expenses grew faster than sales during the period. Despite the margin dip, absolute operating earnings improved significantly, indicating that volume leverage partially offset the efficiency drag.

Capital Raise and Expansion

The company listed on the BSE SME platform in August 2025, raising ₹58.8 crore through a fresh issue of 70 lakh shares at ₹84 per share. The IPO proceeds are being utilized primarily for capital expenditure, including a new manufacturing facility in Mehsana, Gujarat.

As of March 31, 2026, approximately ₹36.2 crore of the IPO proceeds remained unutilised and was parked in fixed deposits. The company has also completed the expansion of its Talod plant, increasing annual production capacity from 720 MT to 4,500 MT.

Balance Sheet Signals

Net worth surged to ₹995.0 crore from ₹354.0 crore in the prior year, driven by the equity infusion from the IPO. The debt-to-equity ratio improved sharply to 0.15 from 0.42, strengthening the financial position. Current assets grew significantly, with cash and cash equivalents rising to ₹365.9 crore from ₹64.1 crore, providing ample liquidity for future capex plans.